HC Wainwright Forecasts Lower Earnings for ADC Therapeutics

Key Points

• HC Wainwright has revised ADC Therapeutics' Q3 2025 earnings estimate downward to ($0.40) per share, a decrease from their earlier projection of ($0.38).
• The company reported a Q2 earnings loss of ($0.50) EPS, missing the analysts' consensus estimate by ($0.14).
• Despite the challenges, ADC Therapeutics maintains a Buy rating from HC Wainwright, with a price target of $7.00.

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings estimates for shares of ADC Therapeutics in a research note issued on Thursday, October 16th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.40) per share for the quarter, down from their prior forecast of ($0.38). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics' Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.62) EPS.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.14). The business had revenue of $18.84 million for the quarter, compared to analyst estimates of $17.82 million.

A number of other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of ADC Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of ADC Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim reiterated a "buy" rating and set a $10.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

ADC Therapeutics Price Performance

Shares of ADCT stock opened at $4.07 on Monday. The company has a market capitalization of $457.88 million, a P/E ratio of -2.59 and a beta of 1.99. The company's 50-day simple moving average is $3.55 and its two-hundred day simple moving average is $2.79. ADC Therapeutics has a one year low of $1.05 and a one year high of $4.74.

Institutional Investors Weigh In On ADC Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cerity Partners LLC purchased a new stake in ADC Therapeutics during the first quarter valued at approximately $25,000. Atria Wealth Solutions Inc. purchased a new stake in ADC Therapeutics during the first quarter valued at approximately $28,000. Russell Investments Group Ltd. lifted its position in ADC Therapeutics by 136.3% during the first quarter. Russell Investments Group Ltd. now owns 39,688 shares of the company's stock valued at $56,000 after acquiring an additional 22,894 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of ADC Therapeutics by 46.2% in the first quarter. MetLife Investment Management LLC now owns 45,487 shares of the company's stock worth $64,000 after buying an additional 14,370 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of ADC Therapeutics in the second quarter worth $96,000. Hedge funds and other institutional investors own 41.10% of the company's stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.